Active substance: metamizole With the publication of the European Commission's decision, the risk assessment procedure on the medicinal products containing metamizole has been completed.

Product group Non-active implants - bone surgery
Reference 09921/25

Product group Injections / Infusions / Transfusions / Dialysis - catheters
Reference 10249/25

Product group In-vitro diagnostics - equipment / products for clinical chemistry
Reference 10467/25

Product group Dressings / Pads - ointments and gels
Reference 08961/25

Product group In-vitro diagnostics - immunological products
Reference 07863/25

Product group In-vitro diagnostics - equipment / products for clinical chemistry
Reference 10395/25

Product group In-vitro diagnostics - immunological products
Reference 09574/25

Product group Medical electronics / Electromedical devices - electrodiagnostics
Reference 09320/25

As of 1^st March 2025 new validation criteria for eCTD submissions are mandatory.

Product group In-vitro diagnostics - equipment / products for clinical chemistry
Reference 08374/25

Product group Non-active implants - cardiac surgery
Reference 05319/25

Product group In-vitro diagnostics - haematological, histological and cytological products
Reference 10399/25

Product group In-vitro diagnostics - immunological products
Reference 07853/25

Product group Active implantable medical devices - artificial hearts
Reference 09716/25

Product group In-vitro diagnostics - equipment / products for clinical chemistry
Reference 08632/25

Product group General equipment for medical treatment - medico-mechanical devices
Reference 05895/25

Product group Physical therapy - inhalation therapy
Reference 01946/25

Product group Medical data processing (software) - Facette_Produktgruppe_09md-07
Reference 08373/25

Product group Orthopaedic / Rehabilitation technology - mobility aids
Reference 08157/25